Name | Oxaliplatin |
Synonyms | L-OHP 1-ohp latin ι-OHP RP-54780 Elocatin platinum NSC-266046 Oxaliplatin OXALIPLATIN oxalic acid oxalatoplatin xalatoplatinum platinum(+2) cation cyclohexane-1,2-diamine (1R,2R)-cyclohexane-1,2-diamine trans-L-Diaminocyclohexane oxalatoplatinum trans-l-diaminocyclohexane oxalatoplatinum oxalato(1r,2r-cyclohexanediammine)platinum(ii) Oxalato(trans-(-)-1,2-cyclohexanediamine)platinum(II) (1,2-cyclohexanediamine-n,n')(ethanedioato(2-)-o,o')-platinu(sp-4-2-(1r-tr (sp-4-2)-((1r,2r)-1,2-cyclohexanediamine-n,n')(ethanedioato(2-)-O,O']platinum [SP-4-2-(1R-TRANS)]-(1,2-CYCLOHEXANEDIAMINE-N,N')[ETHANEDIOATA(2-)-O,O']PLATINUM [SP-4-2-(IR-trans)]-(1,2-cyclohexanediamine-n,n')[ethanedioato(2-)-O,O']-platinum |
CAS | 61825-94-3 63121-00-6 |
EINECS | 621-248-1 |
InChI | InChI=1/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/rC8H14N2O4Pt/c11-7-8(12)14-15(13-7)9-5-3-1-2-4-6(5)10-15/h5-6H,1-4,9-10H2/t5-,6-/m1/s1 |
InChIKey | ZROHGHOFXNOHSO-BNTLRKBRSA-L |
Molecular Formula | C8H12N2O4Pt |
Molar Mass | 395.28 |
Boling Point | 193.6 °C at 760 mmHg |
Specific Rotation(α) | +74.5-78.0 (D/20)(c=0.5,H2O) |
Water Solubility | Soluble in water with heating and/or sonication |
Solubility | Slightly soluble in water, the solubility in water is 7.9 mg/ml; Insoluble in methanol, insoluble in ethanol and acetone. |
Appearance | White loose lumps or amorphous solids |
Color | White to Almost white |
Merck | 14,6912 |
Storage Condition | 2-8°C |
Stability | Stable. Store cool. Incompatible with oxidizing agents. |
Sensitive | Thermal sensitivity |
MDL | MFCD00866327 |
Physical and Chemical Properties | Colorless, thin, triangular-shaped crystals. The solubility in water was 7.9mg/ml. |
Use | Antineoplastic agents for the treatment of rectal cancer |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R40 - Limited evidence of a carcinogenic effect R42/43 - May cause sensitization by inhalation and skin contact. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
UN IDs | 2811 |
WGK Germany | 3 |
RTECS | TP2275850 |
HS Code | 28439000 |
Hazard Class | 6.1(a) |
Packing Group | II |
Toxicity | LD50 intraperitoneal in mouse: 19800ug/kg |
Reference Show more | 1. [IF=6.843] Yuan-Fu Ding et al."Supramolecular nanomedicine derived from cucurbit[7]uril-conjugated nano-graphene oxide for multi-modality cancer therapy."Biomater Sci-Uk. 2021 May;9(10):3804-3813 2. [IF=3.665] Jing Liang et al."Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137."World J Gastroentero. 2020 Apr 7; 26(13): 1474–1489 3. [IF=6.4] Yuxin Sun et al."In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer."Int J Nanomed. 2021 Dec;16:8279-8303 |
is a white loose mass or an amorphous solid. There are also colorless, thin, triangular-shaped crystals. Slightly soluble in water, water solubility of 7. 9 mg/mL; Insoluble in methanol, insoluble in ethanol and acetone.
an aqueous solution of trans-cyclohexanediamine and potassium tetrachloroplatinate was reacted at room temperature to obtain an intermediate product. Silver nitrate was added to the aqueous solution of the intermediate product, and the mixture was stirred in the dark. Then, dipotassium oxalate was added and reacted at room temperature to obtain oxaliplatin.
developed by Sanofi Winthrop in France, launched in France in 1996. Belongs to the new platinum derivatives, the product by producing alkylating conjugates on DNA, the formation of intra-chain and inter-chain cross-linking, thereby inhibiting DNA synthesis and replication, colon cancer, ovarian cancer and melanoma cells can inhibit proliferation. It can be used alone or in combination with fluorouracil in patients with colon cancer or rectal cancer metastasis after failure of fluorouracil treatment.